Trials / Completed

CompletedNCT02679352

SMR Stemless Shoulder Arthroplasty Clinical Study

A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty with SMR STEMLESS

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: 78 (actual)

Sponsor: Limacorporate S.p.a · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Shoulder arthroplasty is a reliable procedure for the treatment of severe shoulder joint diseases to relieve pain and restore shoulder function. Shoulder implants commonly used are characterised by a humeral stem and complications related to the stem are not infrequent. These include: bone stock loss, intraoperative and postoperative break around the implant, malpositioning of the humeral component and difficult eradication of infections inside the bone around the implant. With the aim of reducing stem-related complications, a novel prosthesis characterised by a stem-less design has been developed. The objective of this study is therefore to explore how well people recover after shoulder replacement with this novel stem-less shoulder prosthesis. This will be assessed over 5 years in three different countries in Europe using patient completed questionnaires and clinical and radiographic assessments.

Detailed description

The hypothesis at the base of the study is that the SMR stemless system might contribute to ensure good clinical outcomes and an effective stability and might avoid the potential complications associated with a traditional stemmed implant. The aim of this study is to assess clinical, radiographic and subjective outcomes after anatomic or reverse shoulder arthroplasty with a SMR stemless prosthesis, define the survivorship of the implant and identify possible risk factors that may lead to failure. This is a post-marketing clinical study, because the study device is registered, CE marked and used according to the intended use. It is an international, multi-centre, prospective case series. The assignment of any patient involved in the study is determined by the aetiology preoperatively evaluated by the Investigator and falls within current practice. The decision to use a specific prosthesis design is decided by the Investigators independently and clearly separated from the decision to include the patient in the study. The evaluation has an internal control because the assessment of post-surgery data is compared to baseline measurements (pre-operative clinical analysis and radiographic analysis at discharge). It is open label. The investigation will be carried out in 3 sites in Europe for a maximum total number of 78 treated patients. Accrual will be competitive until the required recruitment target is met. Equal numbers will be recruited at each of three centres (26 patients per site), but a deviation of 8 participants will be accepted (minimum of 18 and maximum of 34 participants recruited per site).

Conditions

Interventions

Type	Name	Description
DEVICE	SMR Stemless	Total anatomic or reverse shoulder arthroplasty

Timeline

Start date: 2016-03-01
Primary completion: 2021-12-01
Completion: 2024-12-01
First posted: 2016-02-10
Last updated: 2025-02-24

Locations

4 sites across 3 countries: Germany, Netherlands, United Kingdom

Source: ClinicalTrials.gov record NCT02679352. Inclusion in this directory is not an endorsement.